Stallergenes Greer is a global biopharmaceutical company specializing in the diagnosis and treatment of respiratory allergies through the development and commercialization of allergy immunotherapy products and services. Our purpose is to enable people with allergies to live normal lives. With more than 1,400 employees worldwide, a presence in 22 countries, and manufacturing facilities in both Europe and the United States, Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France). With complementary strengths, joint heritage and reputations, Stallergenes Greer is driving a continuing leadership in allergy immunotherapy.
London, GB
Size (employees)
1,345 (est)-3%
Stallergenes Greer was founded in 2015 and is headquartered in London, GB
Report incorrect company information

Stallergenes Greer Office Locations

Stallergenes Greer has an office in London
London, GB (HQ)
40 Bernard St
Show all (1)
Report incorrect company information

Stallergenes Greer Financials and Metrics

Stallergenes Greer Financials

Stallergenes Greer's revenue was reported to be £162.34 m in FY, 2016

Revenue (FY, 2016)

162.3 m

Gross profit (FY, 2016)

88 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(52.7 m)

EBITDA (FY, 2016)

(61.7 m)

EBIT (FY, 2016)

(83.7 m)

Market capitalization (2-Oct-2017)

868.9 m

Closing share price (2-Oct-2017)


Cash (1-Mar-2018)

62.1 m
Stallergenes Greer's current market capitalization is €868.9 m.
GBPFY, 2014FY, 2015FY, 2016


71.3 m162.3 m

Cost of goods sold

33.1 m74.3 m

Gross profit

38.2 m88 m

Gross profit Margin, %

GBPFY, 2014FY, 2015FY, 2016


45 k130.8 m62.1 m

Accounts Receivable

25.8 m36.4 m


51.7 m55.6 m

Current Assets

47.4 k235.9 m175.7 m
GBPFY, 2014FY, 2015FY, 2016

Net Income

(44.3 k)(42.9 m)(52.7 m)

Cash From Operating Activities

(13.2 k)(33.3 m)(68 m)

Cash From Financing Activities

66 k385 k3.8 m

Net Change in Cash

45 k130.5 m(68.6 m)
GBPY, 2016

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information